Matches in DBpedia 2016-04 for { ?s ?p "GSK716155 (Albugon) is a recombinant human glucagon-like peptide (GLP)-1-Albumin protein created using Human Genome Sciences' proprietary albumin fusion technology, which involves fusing the gene that expresses human albumin to the gene that expresses a therapeutically active protein (GLP-1)[1]. It is an agonist of the Glucagon-like Peptide-1 Receptor (GLP1R) and underwent clinical drug trials for treatment of Type 2 Diabetes Mellitus. The fusing of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of therapeutically active proteins in the body[1]."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- GSK716155 abstract "GSK716155 (Albugon) is a recombinant human glucagon-like peptide (GLP)-1-Albumin protein created using Human Genome Sciences' proprietary albumin fusion technology, which involves fusing the gene that expresses human albumin to the gene that expresses a therapeutically active protein (GLP-1)[1]. It is an agonist of the Glucagon-like Peptide-1 Receptor (GLP1R) and underwent clinical drug trials for treatment of Type 2 Diabetes Mellitus. The fusing of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of therapeutically active proteins in the body[1].".
- Q5514567 abstract "GSK716155 (Albugon) is a recombinant human glucagon-like peptide (GLP)-1-Albumin protein created using Human Genome Sciences' proprietary albumin fusion technology, which involves fusing the gene that expresses human albumin to the gene that expresses a therapeutically active protein (GLP-1)[1]. It is an agonist of the Glucagon-like Peptide-1 Receptor (GLP1R) and underwent clinical drug trials for treatment of Type 2 Diabetes Mellitus. The fusing of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of therapeutically active proteins in the body[1].".